The list of the second batch of foreign-funded research and development centers eligible for tax exemptions and refunds in 2024 was recently released.
Two centers being operated by companies based in the Taizhou Medical High-tech Zone, located in Taizhou city, East China's Jiangsu province, were included.
They include a product innovation center being run by Nestle Health Science (China) – the local unit of Switzerland-based international health science group Nestle Health Science – and an antibody drug R&D center being operated by pharma company Taizhou Mabtech Pharmaceutical.
As the third global product innovation center under Nestle Health Science, the product innovation center in Taizhou operates in parallel with product innovation centers in the US and Switzerland, sharing advanced core R&D technologies worldwide.
In addition, Taizhou Mabtech Pharmaceutical is a high-tech enterprise engaged in the research and commercialization of antibody drugs. Its antibody drug R&D center focuses on the development of antibody drugs for the treatment of major diseases, such as cancer and immune disorders.
A bird's-eye view of Nestle Health Science (China), located in the Taizhou Medical High-tech Zone. [Photo/WeChat account: weigg6666]